Pharmaxis announce positive results - CF Buzz

Pharmaceutical company Pharmaxis recently announced positive results in its recently completed Phase II trial of Bronchitol in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients. Trial participants had a significant improvement in lung function compared to placebo.

The trial (CF204) was a crossover design with patients aged 6 to 17 years receiving either 400mg of Bronchitol or a placebo twice a day for eight weeks on top of standard of care before a washout period of eight weeks followed by a further eight week treatment period on the alternate treatment.

Read the official statement by Pharmaxis here.



Read More